To gain more insight into the underlying pathobiological mechanism of SF3B1 mutations, we now investigated isogenic cell lines and an additional cohort of treatment-naïve primary CLL samples without a confounding TP53 and/or ATM defect. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.